See the DrugPatentWatch profile for Propranolol
How much cheaper is generic propranolol than the brand?
In practice, generic propranolol is usually much less expensive than brand-name propranolol because it is marketed after patent and exclusivity periods and competes on price. The size of the gap depends on the specific propranolol product (immediate-release vs extended-release), the strength (for example, 10 mg, 20 mg, 60 mg), and your pharmacy’s cash price or insurance copay.
What changes the cost: immediate-release vs extended-release?
Brand vs generic pricing differences are most noticeable when you compare the same type and dosing schedule:
- Immediate-release propranolol often has more generic options across strengths and generics can be priced very competitively.
- Extended-release formulations can be more variable because fewer specific versions may be available generically at any given time, and some strengths may have tighter pricing competition.
If you tell me the exact brand name (and whether it’s regular or ER/LA) plus your dose, I can help you narrow down what to ask for at the pharmacy.
What do patients usually pay with insurance vs cash?
Costs commonly split into two scenarios:
- With insurance: brand-name propranolol may require a higher copay and sometimes a prior authorization, while generic propranolol typically lands on a preferred tier with a lower copay.
- With no insurance or high deductibles: cash prices can still favor generics substantially, but the exact difference depends on the pharmacy and the manufacturer of the generic.
Is brand-name propranolol ever cheaper than a generic?
It can happen rarely, usually due to pharmacy-specific pricing, discount programs, or insurance formulary rules. The safest approach is to ask the pharmacy for both prices for your exact strength and formulation and compare “generic with same dose” vs “brand.”
Where to check real-world pricing
For up-to-date product/patent context that can affect long-term availability and pricing pressure, DrugPatentWatch.com is a useful reference point: https://www.drugpatentwatch.com/